Who
George W. Dunbar Jr.
Director
Company insider
Files Form 4 as: Director, Capricor Therapeutics; President & CEO, Vericel; Director, Achieve Life Sciences; Director, Competitive Technologies.
In numbers
- Trades disclosed
- 60
- Buys
- 4
- Sells
- 0
- Bought
- $56K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 3 Jan 2006
- Last trade
- 5 Jan 2026
- Last filed
- 7 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jan 2026filed 7 Jan 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 19 Dec 2025filed 23 Dec 2025 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 19 Dec 2025filed 23 Dec 2025 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $4,1703,000 at $1.39 | filing |
| 3 Mar 2025filed 4 Mar 2025 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —750 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $1,043750 at $1.39 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,940 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,600 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,250 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,920 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,280 at $0.00 | filing |
| 14 Feb 2023filed 15 Feb 2023 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,401 at $0.00 | filing |
| 14 Feb 2023filed 15 Feb 2023 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $1,9471,401 at $1.39 | filing |
| 3 Jan 2023filed 5 Jan 2023 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,770 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,310 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 29 Mar 2022filed 31 Mar 2022 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,455 at $0.00 | filing |
| 29 Mar 2022filed 31 Mar 2022 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $21K15,455 at $1.39 | filing |
| 29 Mar 2022filed 31 Mar 2022 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K6,300 at $3.41 | filing |
News
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsACHV · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name George W. Dunbar Jr.; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.